Safety analysis by treatment periods from EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular...
| Autor: | Kudo, Masatoshi, Chan, Stephen Lam, Sangro, Bruno, Erinjeri, Joseph P., Qin, Shukui, Ren, Zhenggang, Arai, Yasuaki, Breder, Valeriy Vladimirovich, Lin, Shi-Ming, Peron, Jean-Marie, Nguyen, Tien Quang, Yan, Lunan, Chiu, Chang-Fang, Santos, Florinda A., Veluvolu, Anil, Thungappa, Satheesh Chiradoni, Morgan, Claire, Parsons, Kerry, Xynos, Ioannis, Lencioni, Riccardo |
|---|---|
| Zdroj: | Journal of Clinical Oncology; 2024 Supplement, Vol. 42, p65-65, 48p |
| Databáze: | Supplemental Index |
| Externí odkaz: |
|